Name
osaühing NURME APTEEK
Registry code
10046931
VAT number
EE100403727
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
20.06.1996 (28)
Financial year
01.01-31.12
Capital
2 556.00 €
Activity
47731 - Dispensing chemist in specialised stores
3 145 993 €
188 666 €
6%
2 173 €
(estimate is approximate)
211 555 €
8
Submitted
No tax arrears
89%
38%
Owner | Representative | Beneficial owner | Roles | |
---|---|---|---|---|
Tiiu Vaha 16.11.1965 (58) | 51% - 1 304.00 EUR | Board member (chairman) | Direct ownership | |
Arvo Kallasmaa 17.09.1961 (63) | 49% - 1 252.00 EUR | Board member | Direct ownership |
2019 31.10.2020 | 2020 18.06.2021 | 2021 30.06.2022 | 2022 28.06.2023 | 2023 24.06.2024 | |
---|---|---|---|---|---|
Total Revenue | 2 597 930 € | 2 773 104 € | 2 962 739 € | 2 993 411 € | 3 145 993 € |
Net profit (loss) for the period | 207 986 € | 298 229 € | 217 729 € | 219 414 € | 188 666 € |
Profit Margin | 8% | 11% | 7% | 7% | 6% |
Current Assets | 573 946 € | 661 071 € | 700 404 € | 517 618 € | 503 102 € |
Fixed Assets | 12 988 € | 4 343 € | 204 € | 0 € | 0 € |
Total Assets | 586 934 € | 665 414 € | 700 608 € | 517 618 € | 503 102 € |
Current Liabilities | 149 416 € | 79 668 € | 97 133 € | 94 729 € | 291 547 € |
Non Current Liabilities | 0 € | 0 € | 0 € | 0 € | 0 € |
Total Liabilities | - | - | - | - | - |
Share Capital | - | - | - | - | - |
Equity | 437 518 € | 585 746 € | 603 475 € | 422 889 € | 211 555 € |
Employees | 11 | 10 | 10 | 9 | 8 |
Turnover | State taxes | Labor taxes and payments | Employees | |
---|---|---|---|---|
2024 Q1 | 852 251.25 € | 49 475.56 € | 33 327.78 € | 13 |
2023 Q4 | 891 292.03 € | 136 291.3 € | 41 128.34 € | 12 |
2023 Q3 | 834 237.46 € | 35 983.88 € | 22 606.69 € | 12 |
2023 Q2 | 802 608.28 € | 37 541.33 € | 23 618.73 € | 11 |
2023 Q1 | 790 911.82 € | 42 264.5 € | 26 545.24 € | 12 |
2022 Q4 | 859 436.71 € | 135 663.89 € | 36 415.36 € | 12 |
2022 Q3 | 779 685.62 € | 35 009.01 € | 22 098.97 € | 12 |
2022 Q2 | 758 058.56 € | 37 487.5 € | 21 922.05 € | 12 |
2022 Q1 | 766 878.73 € | 92 957.24 € | 37 719.19 € | 12 |
2021 Q4 | 877 710.68 € | 50 000.22 € | 26 315.98 € | 12 |
2021 Q3 | 811 306.27 € | 44 393 € | 30 100.82 € | 12 |
2021 Q2 | 706 668.12 € | 31 160.59 € | 18 587.7 € | 13 |
2021 Q1 | 742 821.9 € | 77 217.65 € | 29 724.71 € | 12 |
2020 Q4 | 783 441.95 € | 34 276.89 € | 17 644.28 € | 11 |
2020 Q3 | 703 779.48 € | 37 985.12 € | 20 728.95 € | 11 |
2020 Q2 | 777 080.26 € | 37 906.59 € | 18 677.57 € | 11 |
2020 Q1 | 707 606.98 € | 116 985.19 € | 24 387.26 € | 12 |